SCHEMBL4153054

SCHEMBL4153054

O=C(Nc1ccc(N2CCC[C@H](NC(=O)C34CC5CC(C3)C(O)C(C5)C4)C2)cc1)C1CC1

nearest known ligand 0.43

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
CNR1 P21554 1/20 0.43
ALDH1A1 P00352 2/20 0.41
MCHR1 Q99705 2/20 0.38
LMNA P02545 2/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
EPHX2 P34913 1/20 0.37
DEGS1 O15121 1/20 0.37
ME3 Q16798 1/20 0.37
DRD2 P14416 1/20 0.37
DRD3 P35462 1/20 0.37
HRH3 Q9Y5N1 1/20 0.36
GAA P10253 2/20 0.36
KDM4E B2RXH2 2/20 0.36
ABL1 P00519 2/20 0.36
MEN1 O00255 1/20 0.36
KMT2A Q03164 1/20 0.36
MAPT P10636 1/20 0.36
CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4002885 1.00 CNR1 (0.43) CNR1ALDH1A1MCHR1LMNASMN1; SMN2
SCHEMBL4010313 0.91 CNR1 (0.47) CNR1ALDH1A1LMNAEPHX2DRD2
SCHEMBL4011966 0.90 ALDH1A1 (0.46) CNR1ALDH1A1LMNAHRH3GAA
SCHEMBL5950713 0.90 ALDH1A1 (0.46) CNR1ALDH1A1LMNAHRH3GAA
SCHEMBL28769935 0.88 CNR1 (0.43) CNR1ALDH1A1LMNASMN1; SMN2HRH3
SCHEMBL4005560 0.85 CNR1 (0.38) CNR1ALDH1A1DRD2DRD3KMT2A
SCHEMBL5950362 0.85 CNR1 (0.38) CNR1ALDH1A1DRD2DRD3KMT2A
SCHEMBL4148781 0.85 CNR1 (0.48) CNR1ALDH1A1LMNASMN1; SMN2DRD2
SCHEMBL27707859 0.84 CNR1 (0.38) CNR1ALDH1A1DRD2DRD3GAA
SCHEMBL4140568 0.83 EPHX1 (0.43) KMT2ACYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101080226-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-11-28 CN claimed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US claimed
EP-1778229-A4 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORP (US) 2009-06-17 EP disclosed
CN-101080226-A Amido compounds and their use as pharmaceuticals INCYTE CORP (US) 2007-11-28 CN disclosed
EP-1778229-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS Incyte Corporation (US) 2007-05-02 EP disclosed
US-20060122197-A1 Amido compounds and their use as pharmaceuticals INCYTE CORPORATION 2006-06-08 US disclosed
WO-2006020598-A2 AMIDO COMPOUNDS AND THEIR USE AS PHARMACEUTICALS INCYTE CORPORATION (US) 2006-02-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122197-A1 Amido compounds and their use as pharmaceuticals HSD11B1, CYP11B1, HSD11B2 CNR1 516/4885ALDH1A1 311/4885MCHR1 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.